Intellia Therapeutics Inc
NTLA
NASDAQ
Biotechnology
$11.91
USD
+0.08 (+0.68%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.67B
Volume 2.4M
Revenue
$59.51M
TTM
+12.6%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-399.98M
TTM
+16.7%
YoY
Operating Cash Flow
$-346.64M
TTM
+17.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 14.2 | 13.8 | 23.0 | 15.0 | 7.7 |
YoY Growth | +104.8% | +51.3% | +78.8% | -9.5% | -46.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 14.2 | 13.8 | 23.0 | 15.0 | 7.7 |
Selling, General & Administrative | 27.2 | 30.5 | 33.1 | 34.8 | 37.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 124.2 | 125.3 | 121.7 | 115.6 | 120.4 |
Operating Income | -110.0 | -111.5 | -98.7 | -100.5 | -112.8 |
EBITDA | -107.5 | -109.1 | -96.3 | -98.3 | -110.7 |
Other Income / Expense | 1.3 | 3.4 | -3.6 | -0.9 | 0.3 |
Total Other Income / Expense | 8.7 | 10.2 | 2.9 | 4.3 | 6.1 |
Income Before Income Taxes | -101.3 | -101.3 | -95.8 | -96.2 | -106.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -101.3 | -101.3 | -95.8 | -96.2 | -106.6 |
Consolidated Net Income / Loss | -101.3 | -101.3 | -95.8 | -96.2 | -106.6 |
Net Income Attributable to Common Shareholders | -101.3 | -101.3 | -95.8 | -96.2 | -106.6 |
Basic EPS | -$0.98 | -$0.92 | -$0.83 | -$0.81 | -$0.80 |
Diluted EPS | -$0.98 | -$0.92 | -$0.83 | -$0.81 | -$0.80 |
Basic Shares Outstanding | 103.7M | 110.2M | 116.1M | 118.5M | 133.5M |
Diluted Shares Outstanding | 103.7M | 110.2M | 116.1M | 118.5M | 133.5M |